Business Context and Reporting Period
Compugen Ltd. filed this Form 6-K on December 17, 2025, to disclose a material amendment to its license agreement with MedImmune Limited (AstraZeneca Group). The filing relates to the monetization of future royalty rights for the company's drug candidate, rilvegostomig.
Key Financial Metrics
- Upfront Payment: $65 million received from AstraZeneca for a portion of existing royalty interests in rilvegostomig.
- Milestone Payment Increase: The milestone payment associated with the first acceptance of the Biologics License Application (BLA) was increased by $25 million.
- Total Potential Value: The transaction involves an upfront payment plus an increased milestone, totaling up to $90 million in potential value as referenced in the press release title.
- Payment Terms: The $65 million upfront payment is due within five business days of the amendment date (December 16, 2025).
Note: The filing does not provide specific figures for total revenue, net profit, operating cash flow, margins, total debt, or liquidity positions for the reporting period.
Material Changes
The primary material change is the execution of Amendment No. 4 to the March 30, 2018 license agreement. This amendment alters the financial structure of the partnership by converting a portion of future royalty streams into immediate cash and increasing the value of a specific regulatory milestone.
Outlook, Risks, and Management Commentary
- Management Action: Compugen elected to monetize a portion of its future royalty interest to secure immediate liquidity.
- Future Contingencies: The additional $25 million milestone payment is contingent upon the first acceptance of the BLA for rilvegostomig.
- Risks: The filing notes that the summary is subject to the full provisions of the Amendment (Exhibit 10.1), which contains omitted confidential portions. The realization of the milestone payment depends on regulatory acceptance.
Investor Verification Checklist
- Verify the exact percentage of royalty interest sold to AstraZeneca in the full text of Exhibit 10.1.
- Confirm the specific conditions and timing for the $25 million BLA milestone payment.
- Review the company's subsequent financial statements to confirm the receipt of the $65 million upfront payment.
- Assess the impact of this royalty sale on Compugen's long-term revenue potential for rilvegostomig.